2 results match your criteria: "Cardiovascular Research Foundation-Skirball Center for Innovation[Affiliation]"
The Ranger drug-coated balloon: advances in drug-coated technology for treatment of femoropopliteal segment arterial disease.
Future Cardiol
March 2023
Columbia University Medical Center, New York, NY 10032, USA.
Paclitaxel drug-coated balloons (DCBs) have been shown to improve patency and lower revascularization rates compared with plain old balloon angioplasty. DCBs continue to evolve by improving balloon-coating techniques that minimize the quantity of particles washed off into the bloodstream while maximizing drug retention and vascular-healing profile. Against this backdrop, it is clear that the future of antiproliferatives for the superficial femoral artery will focus on enhancements in device coating materials that will improve the efficiency of drug delivery.
View Article and Find Full Text PDFImpact of Paclitaxel Dose on Tissue Pharmacokinetics and Vascular Healing: A Comparative Drug-Coated Balloon Study in the Familial Hypercholesterolemic Swine Model of Superficial Femoral In-Stent Restenosis.
JACC Cardiovasc Interv
July 2015
Cardiovascular Research Foundation-Skirball Center for Innovation, Cardiovascular Research Foundation, Orangeburg, New York; Alizee Pathology, Thurmont, Maryland. Electronic address:
Objectives: This study sought to compare the effect of paclitaxel-coated balloon (PCB) concentration on tissue levels and vascular healing using 3 different PCB technologies (In.Pact Pacific = 3 μg/mm(2), Lutonix = 2 μg/mm(2) and Ranger = 2 μg/mm(2)) in the experimental setting.
Background: The optimal therapeutic dose for PCB use has not been determined yet.